Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Striving to become more patient-centric?

    August 25, 2020 |  

    Explore more with OPEN Health

    Patients are increasingly involved in their healthcare decisions. They have become empowered and informed data-driven advocates for their own health. We are currently at a tipping point in the industry as regulatory bodies and patient advocacy groups have come together to reinforce the importance of the role of patients in the drug development process.

    Why now?

    • Patient engagement tools have evolved considerably
    • There is an increased role of patients in regulatory and health technology decision making
    • Healthcare players who are unable or unwilling to deepen collaborations in the industry may find it difficult, if not impossible, to participate in a future patient-driven healthcare system

    But how does a patient-centric approach evolve from a one-off engagement tactic to a fully integrated, company-wide practice?

    Join us and take an interactive tour through today’s modern approach to patient-centricity. We will show how patient-centricity can be integrated into all phases of development and commercialization and show examples of how to achieve patient buy-in and ensure the patient voice is represented in your study outcomes.

    Start Your Journey

    In this interactive journey, you will:

    • Learn about the value of a patient-centric approach
    • Explore areas to focus on at different phases of the product life cycle
    • See real-life case studies of how a patient-centric approach can be used in therapeutic areas such as oncology, rare disease and advanced therapies
    • Find out how to take your first step to a patient-centric approach
    • Meet our team of experts and what drives them

    Pink divider

    Pharmerit – an OPEN Health Company has been at the forefront of the evolution of patient-centricity. We have seen the positive impact of engaging patients throughout the product lifecycle. We believe it is important to include patient-centricity in every project we undertake, combining expertise with outcomes to see the impact of co-creation.

    This content was provided by OPEN Health

    Company Details

    OPEN Health

    OPEN Health

    Email
    Website

     Latest Content from  OPEN Health 

    OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

    Written by Gavin Jones, OPEN Health

    OPEN Health expands offering with the launch of a new Learning & Development specialist team

    Enhanced expertise to deliver impactful internal training programmes for healthcare clients

    Spotlight interview: 15 minutes on healthcare communications in gene therapy

    Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy

    OPEN Health becomes sponsor of MedComms Networking

    New for 2020, OPEN Health is pleased to announce its sponsorship of MedComms Networking

    OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications

    Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications

    Spotlight interview: 15 minutes on digital in medical communications

    Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications

    Generating data on long-term outcomes with gene and other advanced therapies

    Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.

    Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

    A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

    Spotlight interview: 15 minutes on insights and market research in pharma

    Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

    OPEN Health reflections on the World Orphan Drug Congress in Barcelona

    Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...